Avilex Pharma

Executive Summary

Avilex Pharma is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, founded in 2015. The company specializes in developing best-in-class neuroprotectants targeting the PSD-95 protein in the brain to treat acute neurological conditions. Its lead candidate, AVLX-144, is a small molecule inhibitor of PSD-95 that has completed Phase 1 clinical trials with favorable safety and tolerability data. The program is now advancing into Phase 2 trials for acute ischemic stroke and subarachnoid hemorrhage, two indications with high unmet medical need and no approved neuroprotective therapies. AVLX-144 has the potential to be a first-in-class therapy that reduces neuronal damage and improves functional outcomes, addressing a significant market opportunity in neurology. Looking ahead, Avilex Pharma is poised to achieve several key milestones. The initiation of Phase 2 trials for acute ischemic stroke is expected in the near term, followed by topline data from those studies in 2027. The company may also explore partnering opportunities to support late-stage development and commercialization. As a private company, Avilex benefits from a focused pipeline and strong scientific rationale targeting a validated biological target. The upcoming Phase 2 data will be critical for de-risking the program and could attract strategic partnerships or financing. Avilex represents a high-risk, high-reward opportunity in the cerebrovascular therapeutic space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for acute ischemic stroke90% success
• Q2 2027Topline Phase 2 data for AVLX-144 in acute ischemic stroke or subarachnoid hemorrhage40% success
• TBDPotential partnership or licensing deal for AVLX-14430% success